An expert network of doctors and research scientists is forming the world's first national centre for research into understanding pain in arthritis. Backed by medical research charity the Arthritis Research Campaign and The University of Nottingham, it will aim to improve treatments for arthritis - the most common cause of chronic pain - which affects more than ten million people in the UK. The charity has awarded funding of В 2.5m over five years and the University itself has pledged a further В 3m to support the Nottingham-based Arthritis Research Campaign National Pain Centre investigating mechanisms of pain in arthritis. Key partnerships with local NHS Trusts will further strengthen the new venture. The new centre represents an ambitious bid to tackle chronic pain involving clinicians and scientists from different research fields including rheumatology, neuro-imaging and psychology. These experts will come together in a multi-disciplinary, integrated approach to research better treatments for the painful symptoms of arthritis.
MedImmune Highlights Inflammatory Disease Portfolio At 73rd Annual Meeting Of The American College Of Rheumatology
MedImmune announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. "Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases, " said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma." The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows: -- Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis (Oral Presentation)-Steven Greeberg, Ph.
Medical researchers have long suspected that obscure bacteria living within the intestinal tract may help keep the human immune system in balance. An international collaboration co-led by scientists at NYU Langone Medical Center has now identified a bizarre-looking microbial species that can single-handedly spur the production of specialized immune cells in mice. This remarkable activation of the immune response could point to a similar phenomenon in humans, helping researchers understand how gut-dwelling bacteria protect us from pathogenic bacteria, such as virulent strains of E. coli. The study, published in the Oct. 30, 2009, issue of Cell, also supports the idea that specific bacteria may act like neighborhood watchdogs at key locations within the small intestine, where they sense the local microbial community and sound the alarm if something seems amiss. In mice, at least, the newly identified neighborhood watchdog looks like something out of Disney's "The Shaggy D.A." Distinguished by long hair-like filaments, "These bacteria are the most astounding things I've ever seen, " says Dan Littman, MD, PhD, the Helen L.
Study Results Suggest Oral Salmon Calcitonin Using Eligen R Drug Delivery Technology May Reduce Cartilage And Bone Degradation In Osteoarthritis
Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in which twice-daily oral salmon calcitonin using Emisphere's proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis. The study, a Phase I, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified clinical trial, was conducted on behalf of Emisphere's partner Novartis Pharma AG by Nordic Bioscience, and published online in the September 2009 issue of Osteoarthritis and Cartilage. A total of 73 male and female subjects aged 57 to 75 years with painful osteoarthritis of the knee received twice-daily 0.6 mg or 0.8 mg doses of oral salmon calcitonin with the Eligen® Technology or placebo administered over 14 days. Doses of 0.8mg compared with 0.6mg produced significantly higher Cmax and AUC(0-4 hrs), of calcitonin, P=0.03. This resulted in significant reductions in CTX-I and CTX-II which are biochemical markers of bone degradation and of cartilage degradation, respectively.
Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, according to a new study led by a University of York academic. Researchers conducted the first randomised placebo-controlled trial on the use of both copper bracelets and magnetic wrist straps for pain management in osteoarthritis -- the most common form of the condition. The devices are used worldwide for helping to manage pain associated with chronic musculoskeletal disorders. The results of this trial conflict with those from previous studies, by showing that both magnetic and copper bracelets were ineffective for managing pain, stiffness and physical function in osteoarthritis. The research is published in the latest issue of the journal Complementary Therapies in Medicine. The trial was led by Stewart Richmond, a Research Fellow in the Department of Health Sciences at the University of York, who said: "This is the first randomised controlled trial to indicate that copper bracelets are ineffective for relieving arthritis pain.
Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection. But the molecular and cellular processes triggering these inflammatory and immune responses remain little understood. A group of London-based researchers hope that by extending understanding of the biological processes, they will be able to identify 'biomarkers' in the tissue and blood, which in future could be used to diagnose these conditions, to predict how they will develop and how an individual will respond to treatment. The В 500, 000 research programme is being carried out at National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, working in partnership with King's College Hospital NHS Foundation Trust and Barts and The London School of Medicine and Dentistry Professor Frank Nestle, Mary Dunhill Chair of Cutaneous Medicine and Immunotherapy at King's College London, explains: "We want to test the theory that there are common immunological pathways underlying many chronic inflammatory diseases and that these could serve as valuable biomarkers for diagnostic, prognostic and therapeutic purposes.
Like humans, dogs can also get painful pet arthritis throughout their bodies. But unlike people, who can simply talk about what hurts, how can you spot when your furry little friend has arthritis? Flexcin, the maker of FlexPet dog arthritis treatment, offers these four tell-tail signs so you can bring relief to your pet. 1) No Longer Running & Jumping: Dogs are active animals, even as they age. Running and jumping around are two simple activities enjoyed by happy and healthy dogs. If your dog stops running and jumping, this is the first major sign your pet may have dog joint pain. 2) Difficult Walking Up Stairs: Many homes are built to have multiple levels. If your dog refrains from going upstairs it most likely means they have severe dog joint pain and can't climb the stairs. 3) Overweight: Although done without harmful intentions, a good majority of people overfeed their dogs that can often lead to obesity problems. When a dog is overweight they put too much pressure on their frame and this can lead to uncomfortable pet arthritis.
The National Institutes of Health has announced that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS). Managed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), PROMIS aims to revolutionize the way patient reported outcome tools are selected and employed in clinical research and practice. PROMIS utilizes advances in computer technology and modern measurement theory to assess outcomes such as pain, fatigue, and other aspects of quality of life in a standardized manner. An important goal of the initiative is to develop valid and reliable clinical instruments that will allow the measurement of patient-reported symptoms more efficiently and effectively. "Due to the success of PROMIS and growing interest of various research and health care communities, the NIH Roadmap mechanism has allowed an additional four years of funding for this initiative, " said Raynard S. Kington, M.
The American College of Rheumatology Research and Education Foundation announced that findings through a new research program focused on rheumatoid arthritis have yielded results that will soon alter medical evaluation and management of patients. Highlights of the recent research findings will be presented during a special session on Sunday, October 18, at the American College of Rheumatology Annual Scientific Meeting in Philadelphia, Pa. More than 1.3 million Americans suffer from rheumatoid arthritis, which is the most common forms of inflammatory arthritis. New therapies and advances in genetics, proteomics, pharmacology and genomics have led to major progress in recent years however the cause for, and cure of, RA are currently unknown, and without specialized treatment, bones erode and joints develop deformities. In addition, the estimated U.S. indirect and direct costs of treating RA are $80 billion annually. Despite prevalence in the population, RA receives disproportionately less federal research funding than most other autoimmune diseases.
The Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill School of Medicine garnered numerous research and teaching awards at the recent meeting of the American College of Rheumatology annual scientific conference held Oct. 15-17 in Philadelphia. Thurston is home to huge data sets from ongoing longitudinal studies, including the Johnston County Arthritis Project, that attract top researchers, and faculty are looking at novel areas, including tai chi and the effects of selenium on arthritis. To address clinical needs, and facilitate the translation of research to patient care, the center recently opened a new infusion clinic for rheumatology patients and joined a statewide family practice network to extend its reach and amplify its expertise. "We take our role as the arthritis research center for the people of North Carolina very seriously, " says Joanne Jordan, M.D., the center director and Herman and Louise Smith Distinguished Professor of Medicine at UNC's School of Medicine.